These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 36839644)
1. Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9. Wołowiec Ł; Osiak J; Wołowiec A; Wijata A; Grześk E; Kozakiewicz M; Banach J; Nowaczyk A; Nowaczyk J; Grześk G Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839644 [TBL] [Abstract][Full Text] [Related]
2. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy]. Scheen AJ; Wallemacq C; Lancellotti P Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754 [TBL] [Abstract][Full Text] [Related]
3. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133 [TBL] [Abstract][Full Text] [Related]
4. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
10. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Kosmas CE; Muñoz Estrella A; Skavdis A; Peña Genao E; Martinez I; Guzman E Ther Clin Risk Manag; 2020; 16():1031-1037. PubMed ID: 33149595 [TBL] [Abstract][Full Text] [Related]
11. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
12. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). Sinning D; Landmesser U Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965 [TBL] [Abstract][Full Text] [Related]
14. Inclisiran: How Widely and When Should We Use It? Pirillo A; Catapano AL Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035 [TBL] [Abstract][Full Text] [Related]
15. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Nishikido T Cardiovasc Diabetol; 2023 Jan; 22(1):20. PubMed ID: 36717882 [TBL] [Abstract][Full Text] [Related]
16. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Katsiki N; Vrablik M; Banach M; Gouni-Berthold I Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111334 [TBL] [Abstract][Full Text] [Related]